K-stone

Quick links to important sections

K-stone

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of K-stone

Property Description
Active Ingredients Potassium Citrate and Citric Acid
Form Extended-Release Tablet or Oral Solution
Pharmacological Class Systemic Alkalizing Agent and Potassium Salt
Origin Synthetic/Derived
General Purpose Modifying Urine Chemistry

What Type of Medicine is K-stone? (Identity and Classification)

K-stone is a prescription pharmaceutical preparation primarily classified as a systemic alkalizing agent and a urinary pH modifier. This medication belongs to the Potassium Salt and Alkalizing Agent pharmacological class, working to chemically modify the body's internal acid-base balance. The drug is a combination product, integrating two active components: Potassium Citrate and Citric Acid. Potassium Citrate serves as an alkalizing agent for this purpose.

K-stone is chemically derived, meaning it is a synthetic compound based on naturally occurring substances. It is administered via the oral route and is commonly supplied as either an Extended-Release Tablet, which employs a specialized wax-matrix base for controlled delivery, or as an Oral Solution. The Extended-Release Tablet form is a key feature, designed to provide a steady release of the active ingredients over a prolonged period.


Composition and General Therapeutic Purpose

The core of K-stone's composition is Potassium Citrate, the primary therapeutic component, alongside Citric Acid. The function of this ingredient is contingent upon its metabolism: once absorbed, the citrate is converted into a bicarbonate equivalent, creating an alkaline load that raises the pH of the systemic circulation and, consequently, the urine. Citrate salts function to help regulate urinary mineral balance.

This process of systemic alkalization is essential to the drug's general therapeutic purpose: modifying the chemistry of the urine. By increasing the urine’s pH and significantly elevating the level of urinary citrate (citraturia), K-stone works to create an environment that is chemically unfavorable for the spontaneous formation and aggregation of mineral deposits. For example, its action is typically applied in managing conditions related to hypocitraturic calcium nephrolithiasis. This dual modification of the urinary environment is the fundamental objective of the preparation.

Regulatory References

  1. Potassium Citrate Extended-Release Tablets Drug Label

What side effects are possible with K-stone?

Possible Side Effects and Safety Information

K-stone (potassium citrate) is generally well-tolerated, but like all medications, it can cause side effects. Most common side effects are related to the gastrointestinal (GI) tract.


Common Side Effects

These effects are typically mild and may often be minimized by taking the medication with food or a snack, and a full glass of water. They include:

  • Stomach upset or abdominal discomfort
  • Nausea and vomiting
  • Diarrhea or loose stools

It is also common to notice the shell of the extended-release tablet in your stool. This is normal and means the medication has been properly absorbed.


Serious Side Effects

Though rare, more severe side effects can occur. You should contact a healthcare professional immediately if you experience any of the following:

  • Signs of High Potassium (Hyperkalemia): This can be a serious condition. Symptoms include unusual weakness, tiredness, numbness or tingling, irregular or slow heartbeat, and difficulty breathing. Your potassium levels may be checked by blood tests during treatment.
  • Signs of GI Bleeding or Ulceration: Look out for severe, persistent abdominal pain; severe vomiting; or bloody, black, or tarry stools (which can look like coffee grounds).
  • Allergic Reaction: Symptoms such as hives, difficulty breathing, or swelling of the face, lips, tongue, or throat require immediate medical attention.

Safety Precautions and Contraindications

Potassium citrate should not be used in patients with certain conditions, including pre-existing high potassium levels, active urinary tract infection, uncontrolled diabetes, severe dehydration, or certain gastrointestinal disorders (e.g., peptic ulcer disease, delayed gastric emptying, or intestinal obstruction). It may also interact with other medications, such as potassium-sparing diuretics (e.g., spironolactone) and ACE inhibitors, which can increase the risk of hyperkalemia. Always inform your doctor of all medications and supplements you are taking.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of K-stone is primarily associated with hyperkalemia (high potassium levels in the blood) and gastrointestinal complications.

Symptoms Requiring Urgent Attention

Symptoms of severe hyperkalemia can develop rapidly and may be life-threatening, potentially leading to cardiac arrest. Immediate medical help is required if any of the following serious symptoms occur:

  • Cardiovascular: Slow, uneven, or irregular heartbeat, chest pain, or feeling faint.
  • Neuromuscular: Muscle weakness, a limp or heavy feeling in the limbs, or numbness/tingling sensations (paresthesia) in the hands, feet, or mouth.
  • Respiratory: Shortness of breath or difficulty breathing.

Gastrointestinal Emergencies

Overdosage and the sustained-release nature of the medication carry a risk of localized gastrointestinal damage. You must stop taking the medication immediately and seek emergency medical attention if you experience signs of serious gastrointestinal injury or bleeding, such as:

  • Severe, unrelieved abdominal pain or severe vomiting.
  • Vomiting of blood or material that resembles coffee grounds.
  • Bloody or black, tarry stools.

Overdose risk is elevated in patients with conditions that impair the body's ability to excrete potassium, such as severe renal impairment or certain heart conditions. It is crucial to be aware of these signs and act swiftly if they appear.

Therapeutic Uses of K-stone

What K-stone Treats: Main Uses and Benefits

Potassium citrate, a component of K-stone, is commonly used to help manage conditions associated with stone formation.

This medication is primarily used to support the management of the chronic cycle of stone formation in patients prone to recurrence, particularly those diagnosed with low urinary citrate (hypocitraturia). It is a long-term preventative therapy that addresses the underlying chemical vulnerability, contributing to a reduction in the occurrence of stone episodes, which supports general well-being during symptomatic periods.

The key indications for which K-stone is applied include recurrent calcium oxalate nephrolithiasis (kidney stones), uric acid lithiasis, and the stone-forming tendency associated with Renal Tubular Acidosis (RTA). For uric acid stones, this targeted therapeutic approach provides the practical benefit of may assist with the management of existing stones while also playing a role in managing the formation of new ones.

“K-stone supports the patient during difficult episodes by easing distress and is commonly used for long-term metaphylaxis, which may assist with reducing the risk of future stone episodes.”

This therapy focuses on correcting the specific chemical abnormalities that drive stone development. By addressing these specific systemic imbalances, K-stone contributes to easing the overall symptom load by supporting a reduction in the formation of new stones.

Quick Fact: Support for Recurrent Kidney Stone Management K-stone is relevant when supportive symptom management is appropriate, applied in settings where symptoms are driven by systemic imbalance (hypocitraturia and metabolic acidosis), rather than symptoms related to localized physical injury or structural issues.

Eligibility and Restrictions for Use

Eligibility for K-stone Use: Official Regulatory Information

K-stone (Potassium Citrate) eligibility is strictly defined by regulatory authorities, primarily focusing on populations that are safe from the risk of hyperkalemia (high potassium) and potential gastrointestinal injury.


Populations that Must Not Use K-stone (Contraindications)

Category Prohibited Condition (Official Regulatory Statement)
Potassium Status Hyperkalemia or conditions predisposing to it (e.g., uncontrolled diabetes mellitus, adrenal insufficiency).
Organ Function Severe renal insufficiency (GFR below 0.7 mL/kg/min) or chronic renal failure.
GI Tract Integrity Active peptic ulcer disease or any condition causing arrest or delay in tablet passage (e.g., intestinal obstruction).
Infection Active urinary tract infection.
Medications Concomitant use with potassium-sparing diuretics (e.g., spironolactone).

Restricted and Special Population Use

  • Age: The medicine is formally established for use in adults; its safety and effectiveness in children have not been established by the FDA.
  • Pregnancy/Lactation: Use during pregnancy (US Category C) or lactation is reserved for situations where it is clearly needed.
  • Conditional Use: Use should be avoided in patients with conditions that impair potassium excretion, such as severe heart failure, and requires caution in patients with hepatic impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for K-stone (Potassium Citrate/Citric Acid) is defined by three primary consequences: the presence of potassium, its systemic alkalizing effect, and the nature of its extended-release formulation.


Interaction Scope

Category Description
Medicinal product categories with documented interactions Potassium-sparing diuretics; Angiotensin-Converting Enzyme (ACE) Inhibitors; Angiotensin II Receptor Blockers (ARBs); Nonsteroidal Anti-inflammatory Drugs (NSAIDs); Other potassium salts; Drugs that decrease gastrointestinal transit; Basic/Acidic medications with pH-dependent renal clearance.
Interaction-related restrictions Concomitant administration with Potassium-Sparing Diuretics (e.g., Triamterene, Spironolactone, Amiloride) is strictly contraindicated due to the severe, additive risk of hyperkalemia (high serum potassium) [dailymed.nlm.nih.gov].
Population-specific interaction notes The risk of hyperkalemia from any interacting agent is officially heightened in patients with compromised potassium excretion mechanisms, such as those with chronic renal failure [dailymed.nlm.nih.gov].

Official Interaction Statements

  • Co-administration with ACE Inhibitors, ARBs, and NSAIDs may enhance the risk of hyperkalemia [medicines.org.uk].
  • Systemic alkalization may officially decrease the renal clearance of basic drugs like Quinidine, potentially leading to increased plasma concentrations [medicines.org.uk].
  • Conversely, the alkalizing effect may officially increase the renal clearance of acidic drugs like Salicylates, potentially reducing their therapeutic exposure [medicines.org.uk].
  • Drugs that slow gastrointestinal transit time, such as anticholinergic agents, are documented to enhance the risk of GI lesions due to prolonged contact with the potassium component of the extended-release tablet [dailymed.nlm.nih.gov].

Regulatory documents define the interaction structure based on the additive potassium load, the modification of urinary pH, and the physical constraint related to the extended-release formulation, all of which mandate specific co-administration restrictions.

Mechanism of Action

️ Systemic Alkalization and Metabolic Modulation

The mechanism is initiated by the absorption and subsequent metabolism of the citrate anion (from Potassium Citrate and Citric Acid) into a bicarbonate equivalent ( HCO3^-) within the body’s metabolism. This process provides an alkaline load that modulates the Systemic Acid-Base Buffering System. This systemic pH shift is the prerequisite step required to alter how the kidneys process citrate.


Modulation of Renal Citrate Handling

The resulting mild systemic alkalosis acts upon the Renal Proximal Tubular Cells. This modulates the activity of the NaDC-1 transporter, decreasing the reabsorption and metabolism of filtered citrate. This physiological adjustment leads to an increased urinary citrate concentration (citraturia), which provides high concentrations of a known crystallization inhibitor.


Chemical Chelation and Supersaturation Reduction

The final physiological consequence occurs in the urine, where the high concentration of citrate acts as a chelator of free divalent ions, predominantly calcium ( Ca^2+). This chelation, combined with the alkalinization that increases the solubility of certain solutes, directly reduces the relative supersaturation of solutes in the urine.

Dosage and Administration Information

How to Use K-stone: Administration Guidelines

K-stone is a systemic alkalizing agent that is administered via the oral route as either an Extended-Release Tablet or an Oral Solution, following a structured regimen. The medicine is used for long-term management and relies on a scheduled protocol and laboratory monitoring for correct use. The goal of administration is to maintain specific urinary chemical conditions over time.


Dosing and Administration Protocol

The dosage is not fixed but is titrated based on 24-hour urinary measurements of citrate and pH. Initial dosing is determined by the baseline level of urinary citrate, with an initial dose of 60 mEq per day often used for severe hypocitraturia (urinary citrate <150 mg/day) and 30 mEq per day for milder cases. Dosing should not generally exceed the maximum studied regimen of 100 mEq per day.


Specific Use Instructions

Instruction Type Requirement
Timing & Frequency The total daily dose is divided and taken two, three, or four times per day (BID, TID, or QID). Administration must occur with meals or within 30 minutes after eating.
Tablet Handling Extended-release tablets must be swallowed whole and must not be crushed, chewed, or sucked. The non-absorbable wax matrix base may be seen in the stool, which is an expected consequence of the tablet's design.
Solution Preparation The concentrated Oral Solution must be diluted with a full glass of water or juice before ingestion.

The overall usage protocol requires long-term commitment to the regimen, with adjustments made to maintain urinary pH within the 6.0-7.0 range and to achieve a target urinary citrate concentration of over 320 mg/day. Safety and effectiveness for the extended-release tablet form have not been established in pediatric patients.

Recent Clinical Evidence

Research Evidence / Overview of Studies for K-stone


Evidence for Use in Recurrent Calcium Oxalate Kidney Stones

K-stone has been examined in Randomized Controlled Trials (RCTs) and systematic reviews that have combined findings across multiple trials. This research was primarily applied in adult populations who experience recurring stone episodes, particularly those whose condition involves low urinary citrate (hypocitraturia). The studies monitored key clinical outcomes such as the frequency of new stone events and changes in urinary chemical markers. Studies commonly report measurements of an increase in citrate in the urine and an elevation of urinary pH within the groups that were studied.

Evidence for Use in Uric Acid Stone Management

Research on K-stone has explored its use in uric acid lithiasis, with studies examining both prevention of new stones and the fate of existing uric acid stones. Research primarily examined the modification of urinary pH and observed outcomes related to the physical presence and evolution of uric acid stones. The evidence for this indication is largely derived from studies where sample sizes were modest, and they often focused heavily on the short-term goal of stone dissolution. As a result, the number of large-scale, long-term, randomized studies specifically focused on preventing the recurrence of uric acid stones is limited.

What Remains Uncertain About K-stone Research

A significant limitation across the research field is that long-term effects are not fully established. Follow-up durations were limited in the high-quality RCTs, meaning the existing research provides limited insight into the sustained prevention or potential for stone prevention over many years (e.g., five years or longer). The evidence quality varies across studies, and there is not always consensus on the best way to define and measure success beyond the short-term. The extent of comparative evidence is lacking when considering other strategies for stone prevention.

Frequently Asked Questions (FAQ)

Common questions about K-stone (FAQ)


Q: What is the difference between K-stone and the generic drug name?

K-stone is the brand name for this medication. According to official documents, the generic drug name for the active ingredient is typically Potassium Citrate Extended-Release Tablets. K-stone is a specific commercial product containing this potassium salt.


Q: Is K-stone only used for the condition it was originally approved for?

Regulatory labeling identifies the medication's use for specific conditions, including Renal Tubular Acidosis, Hypocitraturic Calcium Oxalate Nephrolithiasis, and Uric Acid Lithiasis. Official product information is limited to discussing only these approved indications.


Q: Does K-stone contain any common allergens, such as gluten, lactose, or soy?

Official regulatory labels are required to list the active ingredients (Potassium Citrate and Citric Acid) and inactive ingredients like carnauba wax. However, specific information regarding common allergens such as gluten or lactose is not universally specified on the primary drug label.


Q: How long does it usually take for patients to feel the full effects of K-stone?

The medication works to change the chemistry of the urine, which is monitored using 24-hour urinary measurements of citrate and pH. Because the drug's goal is to maintain specific chemical conditions over time, official information does not typically define a specific timeframe for feeling the full clinical effect.


Q: Are there any known foods or drinks that can negatively affect K-stone's function?

Official product information notes the need for caution regarding foods that contain high amounts of potassium, such as some fruits, vegetables, and potassium-containing salt substitutes. This is because K-stone itself contains potassium, and consuming too much of it may increase the risk of hyperkalemia (high serum potassium).


Q: What should be done if a patient forgets to take a dose of K-stone?

Official guidelines describe the process for a missed dose: if remembered soon after, the dose is typically taken; if near the next dose, the missed dose is omitted. The product information specifies that a double dose should not be taken to make up for a missed one.


Q: What are the common clinical scenarios that lead to stopping K-stone?

Official documents indicate that discontinuation of the medication is warranted if the patient experiences signs of serious injury to the gastrointestinal tract. These symptoms include severe vomiting, abdominal pain, or gastrointestinal bleeding (e.g., bloody or black stools).


Q: Does K-stone have any reported effects on mood, concentration, or mental clarity?

While not listed as a common effect, official reports on severe side effects related to hyperkalemia (high potassium) can include effects on the central nervous system. These documented symptoms may include feelings of confusion or nervousness.


Q: Do the side effects from K-stone typically lessen or disappear over time?

The most common side effects are related to the gastrointestinal tract and are typically mild, often minimized by taking the medication with food. Official regulatory documents do not provide data or assurance on whether these common effects lessen or resolve completely over time.


Q: Are there any known long-term side effects from taking K-stone for several years?

Regulatory documents note that the risk of serious side effects, such as gastrointestinal lesions (damage to the GI lining), is higher if the drug is taken for a long duration or in high doses. This risk is related to the physical properties of the extended-release tablet.


Q: Is it known if K-stone can affect liver or kidney function?

Official information states that K-stone is contraindicated (should not be used) in patients with pre-existing conditions that impair potassium excretion, such as severe renal insufficiency. The drug label does not cite liver function as a primary concern.


Q: What are the officially documented symptoms if a person takes more K-stone than recommended?

Symptoms of taking more than the recommended amount primarily reflect those of severe hyperkalemia. These officially documented symptoms include abdominal pain, confusion, difficult breathing, an irregular heartbeat, and tingling or numbness in the extremities.


Q: What is the general recommendation regarding consuming alcohol while taking K-stone?

Official product information indicates that consuming alcohol while taking the medication may increase the rate of dissolution of the extended-release tablet. This effect can potentially lead to a loss of the modified-release action of the drug.


Q: Does K-stone interact with over-the-counter pain relievers such as ibuprofen or acetaminophen?

Co-administration with Ibuprofen, which is an NSAID, may enhance the risk of hyperkalemia (high potassium). Regulatory documents state that acetaminophen has no known regulatory interaction, but the product label specifies limits for the maximum recommended daily dosage of acetaminophen.


Q: Can K-stone affect the effectiveness of hormonal birth control?

The medication is known to interact with certain hormonal contraceptives containing the progestin drospirenone due to an additive risk of hyperkalemia. The regulatory labeling does not specify its effect on the contraceptive effectiveness of other types of hormonal birth control.


Q: Can patients with pre-existing high blood pressure or diabetes use K-stone?

The use of K-stone is contraindicated in patients with uncontrolled diabetes mellitus. The label does not specifically contraindicate the drug for general high blood pressure, but cautions are advised for conditions such as severe heart failure.


Q: Is K-stone contraindicated for patients with a history of heart problems?

The product information states that use of the medication is not recommended in patients with conditions that impair the body's ability to excrete potassium, such as severe myocardial damage (heart muscle damage) or severe heart failure. These conditions increase the risk of serious high potassium levels.


Q: Does K-stone affect fertility or reproductive health?

Official regulatory documents state that it is unknown whether potassium citrate affects fertility in humans. However, related animal studies conducted with citric acid did not show an effect on reproductive health.


Q: What does the term 'contraindication' mean when found on the K-stone product label?

A contraindication is an official term describing a condition or factor that presents a high risk and serves as a reason to withhold a particular medical treatment. Using the drug despite a contraindication significantly increases the risk of harm to the patient.


Q: Why must K-stone be stored away from excessive heat and light?

K-stone must be stored in a tightly closed container at controlled room temperature to ensure the product remains stable. Official storage instructions indicate that the tablets must be protected from moisture, excessive heat, and direct light, as these factors can compromise the medication's effectiveness.


Q: How is K-stone processed and eliminated by the body?

The drug is processed in the body via the metabolism of absorbed citrate, which is converted into an alkaline substance. This substance then alters how the kidneys handle citrate, leading to higher levels in the urine. The final elimination of the drug primarily occurs through the kidneys.

How should K-stone be stored and disposed of?

The storage and disposal of K-stone (Potassium Citrate Extended-Release Tablets) must adhere strictly to official regulatory requirements to maintain product integrity and safety.


Storage Requirements

K-stone must be stored at Controlled Room Temperature, specifically between 20°C to 25°C (68°F to 77°F). The container must be kept tightly closed to protect the tablets from moisture and excessive heat, which can compromise the formulation's stability. As a mandatory safety requirement, the medicine must be stored out of the reach of children.


Disposal Instructions

Unused or expired K-stone product must be disposed of in compliance with local regulations for pharmaceutical waste, following official federal or state guidelines. It should not be disposed of in general household waste or flushed down wastewater unless specifically instructed by regulatory guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of K-stone found in:

A-Z Index: